L3VLUP
ProSign in

ALEC · GILD in the 13F filings

Two to four stocks side by side among the 95 tracked managers: who lists them, how that has moved, who bought and sold in a quarter, and which managers hold more than one.

ALECGILD
Quarter
Q2 2026Q1 2026Q4 2025Q3 2025Q2 2025Q1 2025Q4 2024Q3 2024Q2 2024Q1 2024Q4 2023

Holders over time

Tracked managers listing each stock every quarter, at least, or their combined reported value. A gap is a quarter in which no tracked manager listed it. Click a quarter to compare there.
  • ALEC
  • GILD
010203040202120222023202420252026
Holders and value by quarter
QuarterALECGILD
Q3 20203 holders, $3.2m25 holders, $14.2bn
Q4 20202 holders, $4.0m27 holders, $13.4bn
Q1 20212 holders, $7.2m24 holders, $14.5bn
Q2 20212 holders, $8.2m18 holders, $14.9bn
Q3 20213 holders, $20m20 holders, $16.4bn
Q4 20213 holders, $31m20 holders, $16.8bn
Q1 20221 holders, $5.6m28 holders, $13.2bn
Q2 20221 holders, $3.6m26 holders, $13.6bn
Q3 20221 holders, $3.5m24 holders, $13.3bn
Q4 20222 holders, $4.1m32 holders, $21.1bn
Q1 20232 holders, $2.9m27 holders, $21.8bn
Q2 20233 holders, $2.9m24 holders, $20.7bn
Q3 20231 holders, $2.4m24 holders, $20.0bn
Q4 20232 holders, $2.9m22 holders, $21.5bn
Q1 20244 holders, $11m30 holders, $20.3bn
Q2 20242 holders, $1.3m28 holders, $18.5bn
Q3 20241 holders, $367k29 holders, $24.2bn
Q4 2024none listed holders, n.a.28 holders, $25.9bn
Q1 2025none listed holders, n.a.33 holders, $32.0bn
Q2 2025none listed holders, n.a.27 holders, $30.9bn
Q3 2025none listed holders, n.a.23 holders, $29.4bn
Q4 2025none listed holders, n.a.25 holders, $34.3bn
Q1 2026none listed holders, n.a.25 holders, $38.5bn
Q2 2026none listed holders, n.a.26 holders, $34.2bn
ALEC

Alector Inc

Holders
1
Reported value
$367k
Buyers
0
Sellers
1

Breadth -1 among 94 comparable managers.

Pharmaceuticals and biotechnologyBiological productsHealthcare: biopharma and medtech · L3VLUP
GILD

Gilead Sciences Inc

Holders
29
Reported value
$24.2bn
Buyers
15
Sellers
15

Breadth 0 among 94 comparable managers.

Pharmaceuticals and biotechnologyBiological productsHealthcare: biopharma and medtech · L3VLUP

Who holds both, Q3 2024

Among the 30 tracked managers listing any of them. "Only" is about listed positions: a manager may hold the other below its listed range.

Both (0)

No tracked manager lists every one of them.

Only ALEC (1)

Baillie Gifford & Co

Only GILD (29)

Acadian Asset Management LLC, AllianceBernstein LP, AQR Capital Management LLC, Arrowstreet Capital LP, Balyasny Asset Management LLC, Bridgewater Associates LP, Capital Research Global Investors, Capital World Investors, Caxton Associates LLP, Citadel Advisors LLC, D. E. Shaw & Co., Dodge & Cox, ExodusPoint Capital Management LP, Fidelity (FMR LLC), Hudson Bay Capital Management LP, Invesco Ltd, Janus Henderson Group Ltd, Man Group PLC, Marshall Wace LLP, Millennium Management LLC, PDT Partners LLC, Point72 Asset Management LP, Renaissance Technologies LLC, Schonfeld Strategic Advisors LLC, T. Rowe Price Associates Inc, and 4 more

How much of the picture this is

A 13F is a manager’s long US-listed equity book at a quarter end, filed up to 45 days later. Buyers and sellers count comparable managers (those that filed both quarters) by shares, so a rise in value with no rise in shares is the price. Large books are listed to their largest positions. These are 95 tracked managers, not the institutional market.

Back to the 13F Explorer →